Phase II Study Evaluating the Efficacy and Tolerance of Bevacizumab (Avastin) in HER2- Inflammatory Breast Cancer (Beverly1)

NCT00820547 Phase 2 COMPLETED

RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving bevacizumab and combination chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving bevacizumab and radiation therapy after surgery may kill any tumor cells that remain after surgery. PURPOSE: This phase II trial is studying giving bevacizumab together with chemotherapy before surgery and bevacizumab and radiation therapy after surgery to see how well it works in treating patients with inflammatory breast cancer.

Details

Lead sponsor	UNICANCER
Phase	Phase 2
Status	COMPLETED
Enrolment	100
Start date	2009-01
Completion	2019-09

Conditions

• Breast Cancer

Interventions

• bevacizumab
• cyclophosphamide
• docetaxel
• epirubicin hydrochloride
• fluorouracil

Primary outcomes

• Complete histologic response rate — Post surgery

Countries

France